银屑病患者接受生物制剂后体重与BMI变化:系统综述与网状Meta分析
该系统综述与网状Meta分析纳入6项研究共862例银屑病患者,评估不同生物制剂治疗前后体重和BMI变化。与常规系统治疗相比,TNF-α抑制剂与体重(平均差1.40 kg,95%CI 0.88-1.93 kg)和BMI(0.39 kg/m2,95%CI 0.24-0.54 kg/m2)显著增加相关,而抗IL-12/23或抗IL-17生物制剂未见显著增加。
要点
- TNF-α抑制剂治疗与银屑病患者体重和BMI显著增加相关。
- 抗IL-12/23或抗IL-17生物制剂未发现体重或BMI显著增加。
- 超重和肥胖患者启动生物制剂前应考虑该关联。
核心结论
- TNF-α抑制剂治疗似乎与银屑病患者体重和BMI增加相关,而抗IL-12/23和抗IL-17生物制剂治疗则无此关联。
研究设计与样本
- 系统综述与网状Meta分析,检索Medline、Embase和Cochrane Central Register of Controlled Trials至2019年3月1日,纳入6项研究共862例银屑病患者,使用Newcastle-Ottawa量表评估偏倚风险。
主要发现
- 与常规系统治疗相比,TNF-α抑制剂治疗与体重显著增加相关(平均差1.40 kg,95%CI 0.88-1.93 kg)。
- 与常规系统治疗相比,TNF-α抑制剂治疗与BMI显著增加相关(平均差0.39 kg/m2,95%CI 0.24-0.54 kg/m2)。
- 接受抗IL-12/23或抗IL-17生物制剂治疗的患者未发现体重或BMI显著增加。
临床怎么用
- 对超重和肥胖的银屑病患者,在启动生物制剂治疗前应考虑不同生物制剂对体重和BMI的潜在影响。
局限性
- 仅1项研究报告了接受抗IL-17生物制剂治疗患者的体重和BMI。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies have suggested that biologic therapy for psoriasis might relate to body weight gain. OBJECTIVE: To assess the changes in body weight and body mass index (BMI) in psoriasis patients after receiving various biologics. METHODS: We conducted a systematic review and network meta-analysis to evaluate the changes in body weight and BMI in psoriasis patients receiving biologics. On March 1, 2019, we searched Medline, Embase, and Cochrane Central Register of Controlled Trials for relevant studies. The Newcastle-Ottawa scale was used to assess the risk of bias. RESULTS: We included 6 studies with 862 psoriasis patients. Compared with conventional systemic treatments, treatment with tumor necrosis factor α inhibitors was associated with a significant increase in body weight (mean difference 1.40 kg, 95% confidence interval 0.88-1.93 kg) and BMI (0.39 kg/m2, 95% confidence interval 0.24-0.54 kg/m2). In contrast, no significant increase in body weight or BMI was found among patients receiving anti-interleukin (IL)-12/23 or anti-IL-17 biologics. LIMITATIONS: Only 1 study reported body weight and BMI for patients receiving the anti-IL-17 biologic. CONCLUSION: Tumor necrosis factor α inhibitor treatment appears to be associated with an increase in body weight and BMI, and treatment with anti-IL-12/23 and anti-IL-17 biologics do not. This association should be considered before initiating biologics for overweight and obese patients.
引用
- Wu MY, Yu CL, Yang SJ, et al. Change in body weight and body mass index in psoriasis patients receiving biologics: A systematic review and network meta-analysis. J Am Acad Dermatol. 2019. PMID: 31400455. doi:10.1016/j.jaad.2019.07.103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。